23 results for "S. Graham"
Showing 1–20 · 1.92 seconds · RSS
-
Journal Article
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
The development of effective vaccines to combat infectious diseases is a complex multi-year and multi-stakeholder process. To accelerate the development of vaccines for coronavirus disease 2019 (COVID-19), a novel pathogen emerging in late 2019 and spreading globally by early 2020, the United…
-
Journal Article Full text
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure…
-
Journal Article Full text
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
-
Journal Article Full text
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Variant SARS-CoV-2 and the mRNA-1273 Vaccine How well do serum samples from persons vaccinated with the mRNA-1273 vaccine neutralize the P.1 lineage, the B.1.1.7 lineage, the B.1.1.7 lineage plus t...
-
Journal Article Full text
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. Methods In this prospective…
-
Journal Article
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
To assess infection and vaccine-Induced Neutralizing-Antibody activity against the SARS-CoV-2 B.1.617.1 (or kappa) and B.1.617.2 (or delta) variants.
-
Journal Article Full text
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study
BACKGROUND: COVID-19 vaccines show excellent efficacy in clinical trials and effectiveness in real-world data, but some people still become infected with SARS-CoV-2 after vaccination. This study aimed to identify risk factors for post-vaccination SARS-CoV-2 infection and describe the…
-
Journal Article
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
-
Journal Article
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe…
-
Journal Article
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody tit...
-
Journal Article
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. METHODS: We…
-
Journal Article
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
BACKGROUND: Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age…
-
Journal Article Full text
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label…
-
Journal Article Full text
Broad neutralization of SARS-related viruses by human monoclonal antibodies
Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified…
-
Journal Article Full text
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
-
Journal Article Full text
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study
Background The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in England. We aimed to investigate whether increases in the proportion of infections with this variant are associated with differences in symptoms or disease course, reinfection rates, or transmissibility. Methods We…